

Electronic Acknowledgement Receipt

EFS ID:	5567314
Application Number:	10564647
International Application Number:	
Confirmation Number:	1467
Title of Invention:	Human antibody molecules for il-13
First Named Inventor/Applicant Name:	Philip David Monk
Customer Number:	44992
Filer:	Christine Catherine McCormack
Filer Authorized By:	
Attorney Docket Number:	102789-1P US
Receipt Date:	23-JUN-2009
Filing Date:	19-JUL-2006
Time Stamp:	14:32:00
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/Message Digest	Multi Part/.zip	Pages (if appl.)
1	Information Disclosure Statement (IDS) Filed (SB/08)	IDSform10564647option1.pdf	94847 90ca67b6fda0ecc67212843e98102e1898d dd4d4	no	5

Warnings:

Information:

This is not an USPTO supplied IDS fillable form

2	Information Disclosure Statement (IDS) Filed (SB/08)	statement10564647option1. pdf	25441 23bfd559e0da2d6d837e6b271053b24640 b825c7	no	3
---	---	----------------------------------	---	----	---

Warnings:

Information:

This is not an USPTO supplied IDS fillable form

3	NPL Documents	harlow.pdf	610986 eb0283d9cf7ea4b2b462bcf989afb21e89fb 4dc4	no	9
---	---------------	------------	--	----	---

Warnings:

Information:

4	NPL Documents	Heinrichsoption1.pdf	858074 79b94b4ee58d0304a25f8859fb106e04fd2 1bbd3	no	11
---	---------------	----------------------	--	----	----

Warnings:

Information:

5	NPL Documents	madhankumaroption1.pdf	2117438 9c52f84e6de45b28324478a509671772cac 153a7	no	12
---	---------------	------------------------	---	----	----

Warnings:

Information:

6	NPL Documents	makitalooption1.pdf	583471 6c2100506fcf4edbae432d5165bba604fa60 35d2	no	13
---	---------------	---------------------	--	----	----

Warnings:

Information:

7	NPL Documents	eduardopadlanoption1.pdf	3974848 7fb68545e9ecf0cb2689d5bb5bc57e1c6dcc 7b40	no	49
---	---------------	--------------------------	---	----	----

Warnings:

Information:

8	NPL Documents	portolanooption1.pdf	597005 5135fe741952c26eb4535f02eaa1c1f05c64 7e59	no	8
---	---------------	----------------------	--	----	---

Warnings:

Information:

9	NPL Documents	vajidosoption1.pdf	700285 ac16033f50bc6e1299393b26a5edc88bc48 be1a0	no	14
---	---------------	--------------------	--	----	----

Warnings:

Information:

Total Files Size (in bytes):			9562395
-------------------------------------	--	--	---------

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.